21 CFR 876.5550 — Agents, Embolic, For Treatment Of Benign Prostatic Hyperplasia
Gastroenterology, Urology (GU) · Subpart F—Therapeutic Devices · § 876.5550
Identification
A prostatic artery embolization device is an intravascular implant intended to occlude the prostatic arteries to prevent blood flow to the targeted area of the prostate, resulting in a reduction of lower urinary tract symptoms related to benign prostatic hyperplasia. This does not include cyanoacrylates and other embolic agents which act by in situ polymerization or precipitation, or embolization devices used in neurovascular applications (see 21 CFR 882.5950).
Classification Rationale
Class II (special controls). The special controls for this device are:
Product Codes
| Product Code | Device Name | Class | Devices | Attributes |
|---|---|---|---|---|
| NOY | Agents, Embolic, For Treatment Of Benign Prostatic Hyperplasia | 2 | 4 | Implant |
Special Controls
NOY — Agents, Embolic, For Treatment Of Benign Prostatic Hyperplasia
In combination with the general controls of the FD&C Act. the prostatic artery embolization device is subject to the following special controls:
De Novo Order DEN160040
NOY — Agents, Embolic, For Treatment Of Benign Prostatic Hyperplasia
*Classification.* Class II (special controls). The special controls for this device are:(1) The device must be demonstrated to be biocompatible. (2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: (i) Evaluation of suitability for injection through catheters intended for use in embolization; and (ii) Evaluation of the size distribution of the device. (3) Performance data must support the sterility and pyrogenicity of the device. (4) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life. (5) Clinical data must evaluate post-embolization damage due to non-target embolization under anticipated use conditions. (6) The labeling must include: (i) Specific instructions on safe device preparation and use; (ii) The device shelf life; (iii) Data regarding urinary retention; and (iv) Data regarding post-prostatic artery embolization syndrome.
eCFR
NOY — Agents, Embolic, For Treatment Of Benign Prostatic Hyperplasia
(1) The device must be demonstrated to be biocompatible. (2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: (i) Evaluation of suitability for injection through catheters intended for use in embolization; and (ii) Evaluation of the size distribution of the device. (3) Performance data must support the sterility and pyrogenicity of the device. (4) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life. (5) Clinical data must evaluate post-embolization damage due to non-target embolization under anticipated use conditions. (6) The labeling must include: (i) Specific instructions on safe device preparation and use; (ii) The device shelf life; (iii) Data regarding urinary retention; and (iv) Data regarding post-prostatic artery embolization syndrome.
Ecfr Llm
